Compare Eaton Corporation plc (ETN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Incyte Corporation — how do they compare? Eaton Corporation plc trades at $429.65 (market cap $164.88B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Eaton Corporation plc is far larger — about 7.2× Incyte Corporation's market cap, and Eaton Corporation plc pays a 1.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Incyte Corporation for 33 Days on average.
| ETN | INCY | |
|---|---|---|
Market Cap | $164.88B | $22.85B |
Volume | 2,535,086 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $459.96 | $129.93 |
52-Week Low | $315.82 | $83.80 |
Typical Hold Time | 31 Days | 33 Days |
Enterprise Value | $185.51B | $18.35B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton (ETN) trades at $424.51, down 1.58% over the past day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong profitability metrics include a 12.75% net income margin and 19.71% ROE. Recent news highlights strategic acquisitions in data center and utility markets, positioning the company for durable growth from AI and grid modernization trends.
Outlook remains positive with a consensus price target of $502.38, implying significant upside. Risks include execution of acquisitions and potential margin pressure from increased investing outlays. Analyst sentiment is strongly bullish with 70% buy ratings, though technical indicators suggest near-term caution.
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
